Clinical Impact of Autologous Cell Therapy on Hypoplastic Left Heart Syndrome after Bidirectional Cavopulmonary Anastomosis.

TitleClinical Impact of Autologous Cell Therapy on Hypoplastic Left Heart Syndrome after Bidirectional Cavopulmonary Anastomosis.
Publication TypeJournal Article
Year of Publication2020
AuthorsVincenti M, O'Leary PW, M Qureshi Y, Seisler DK, Burkhart HM, Cetta F, Nelson TJ
Corporate AuthorsWanek HLHS Consortium Clinical Pipeline
JournalSemin Thorac Cardiovasc Surg
Date Published2020 Nov 07

Preservation of right ventricle function (RV) is a key to favorable outcome in Hypoplastic Left Heart Syndrome (HLHS), but methods to preserve or improve RV function are limited. Our goal was to assess the clinical and functional impact of autologous umbilical cord blood-derived mononuclear cells (UCB-MNC) therapy when given to patients with HLHS at Stage II surgery. UCB-MNC patients were enrolled prospectively in a phase I, FDA monitored trial as previously described (Burkhart et. al., 2019). Matched retrospective controls were identified by review of clinical databases. Growth and RV echocardiographic variables were assessed in both groups pre-stage II through the first 6 months postoperatively. Statistical comparisons between the groups at similar post-operative time points were made to define potential impact of the cell therapy. There were 7 UCB-MNC patients and 17 controls. Pre-stage II, most parameters showed no differences between groups, although median fractional area change (FAC) was slightly greater in the controls (FAC: controls = 45% vs. UCB-MNC = 41% p=0.02). At dismissal, FAC and estimated Ejection Fraction (EF) decreased in controls, while both were unchanged from baseline in UCB-MNC patients (ΔFAC: -5% vs. -1%, p<0.01; ΔEF: -8% vs. 0%, p=0.03 respectively). Subsequently, median FAC increased slightly in UCB-MNC patients over the 6 month follow-up period, while it decreased in controls (ΔFAC: UCB-MNC +3% vs. control -5%, p=0.03). Preoperative weight percentiles were similar in both groups (UCB-MNC 34%ile vs controls 22%ile, p=0.93). However, by 6 months post-operative, median weight percentile improved to 63% in the UCB-MNC treated group, but declined to 8% in controls (p=0.02). UCB-MNC therapy appears to limit the initial negative impact on RV FAC and EF seen after stage II surgery. During early follow up, FAC and weight percentile improved in UCB-MNC patients relative to controls, suggesting a beneficial effect of UCB-MNC therapy.

Alternate JournalSemin Thorac Cardiovasc Surg
PubMed ID33171247